Clinical Report: Interconnected Mechanisms of Hypertension and Dyslipidemia in CVD
Overview
This review examines the mechanisms of hypertension and dyslipidemia in cardiovascular disease (CVD) progression, highlighting key molecular pathways and emerging targeted therapies.
Background
Cardiovascular disease (CVD) is a leading cause of global mortality, with hypertension and dyslipidemia being significant contributors to its progression. The coexistence of these conditions amplifies vascular inflammation and metabolic dysregulation.
Data Highlights
No numerical data or trial data provided in the source material.
Key Findings
Hypertension and dyslipidemia interact through molecular pathways, increasing CVD risk.
Key pathways include the RAAS/PPAR axis, AMPK/SIRT1 signaling, and NLRP3 inflammasome activation.
The interplay of these conditions disrupts endothelial function and promotes chronic inflammation.
Emerging therapies include RAAS inhibitors combined with statins and PCSK9 inhibitors.
Multi-target strategies may improve clinical outcomes.
Clinical Implications
Healthcare professionals should consider the combined effects of hypertension and dyslipidemia when managing patients at risk for CVD.
Conclusion
This review summarizes the relationship between hypertension and dyslipidemia in CVD.
Patients are mining Reddit and TikTok for symptom intel while you're not — and a small study calls it epistemic injustice. Different knowledge, mutually unrecognized. Maybe ask where they've been reading before you wave it off as anecdote.
